Dynamic Evaluation of the Modified Glasgow Prognostic Scale in Patients With Resected, Localized Clear Cell Renal Cell Carcinoma



      To evaluate the relationship between dynamic changes in the modified Glasgow Prognostic Scale (mGPS) and postnephrectomy survival among localized clear cell renal cell carcinoma (ccRCC) patients.


      We retrospectively identified patients who underwent nephrectomy for localized ccRCC with preoperative mGPS = 0 from 2005 to 2018. The primary exposure of interest was ΔmGPS between 2 points – 60 days prior to surgery and 1 year after surgery. We assessed the relationship between ΔmGPS and survival outcomes. Kaplan-Meier curves were generated to determine survival estimates and Cox proportional hazards models were fit to estimate hazard ratios (HRs). Multivariable models were constructed using both ΔmGPS and clinical variables known to be associated with differences in survival.


      We identified 313 patients for our analytic cohort with a median follow-up time of 20.2 months. Thirty-seven (11.9%) patients died and 39 (12.54%) showed recurrence during follow-up. Two hundred sixty-three (84.6%) patients had unchanged mGPS before and after surgery, while 48 (15.4%) patients showed an increase in postoperative mGPS from preoperative mGPS. Compared to patients with unchanged mGPS, patients with a higher postoperative mGPS had an increased risk of death (HR = 3.05 [1.39-6.68], P = .005) and recurrence (HR = 2.98 [1.34-6.64], P = .008).


      Patients with an increase in mGPS following nephrectomy for ccRCC were more likely to die and experience cancer recurrence. Assessing dynamic changes in this cheap, validated, and reproducible test may be useful in identifying patients at higher risk for more aggressive disease or for counseling patients regarding risk of cancer recurrence.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Urology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Jemal A
        • Bray F
        • Center MM
        • Ferlay J
        • Ward E
        • Forman D
        Global cancer statistics.
        CA Cancer J Clin. 2011; 61: 69-90
        • King SC
        • Pollack LA
        • Li J
        • King JB
        • Master VA
        Continued increase in incidence of renal cell carcinoma, especially in young patients and high grade disease: United States 2001 to 2010.
        J Urol. 2014; 191: 1665-1670
        • Chin AI
        • Lam JS
        • Figlin RA
        • Belldegrun AS
        Surveillance strategies for renal cell carcinoma patients following nephrectomy.
        RevUrol. 2006; 8: 1-7
        • Canna K
        • McMillan DC
        • McKee RF
        • McNicol AM
        • Horgan PG
        • McArdle CS
        Evaluation of a cumulative prognostic score based on the systemic inflammatory response in patients undergoing potentially curative surgery for colorectal cancer.
        Br J Cancer. 2004; 90: 1707-1709
        • Jabs WJ
        • Busse M
        • Kruger S
        • Jocham D
        • Steinhoff J
        • Doehn C
        Expression of C-reactive protein by renal cell carcinomas and unaffected surrounding renal tissue.
        Kidney Int. 2005; 68: 2103-2110
        • McKeown DJ
        • Brown DJ
        • Kelly A
        • Wallace AM
        • McMillan DC
        The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer.
        Br J Cancer. 2004; 91: 1993-1995
        • Johnson TV
        • Young AN
        • Osunkoya AO
        • Master VA
        C-reactive protein as a clinically useful biomarker of metastasis of renal cell carcinoma.
        Mol Diagn Ther. 2010; 14: 191-193
        • Karakiewicz PI
        • Hutterer GC
        • Trinh QD
        • et al.
        C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients.
        Cancer. 2007; 110: 1241-1247
        • Lamb GW
        • McArdle PA
        • Ramsey S
        • et al.
        The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer.
        BJU Int. 2008; 102: 756-761
        • Proctor MJ
        • Morrison DS
        • Talwar D
        • et al.
        An inflammation-based prognostic score (mGPS) predicts cancer survival independent of tumour site: a Glasgow Inflammation Outcome Study.
        Br J Cancer. 2011; 104: 726-734
        • Shim SR
        • Kim SJ
        • Kim SI
        • Cho DS
        Prognostic value of the Glasgow Prognostic Score in renal cell carcinoma: a meta-analysis.
        World J Urol. 2017; 35: 771-780
        • Tai CG
        • Johnson TV
        • Abbasi A
        • et al.
        External validation of the modified Glasgow prognostic score for renal cancer.
        Indian J Urol. 2014; 30: 33-37
        • Sobin LH
        • Fleming ID
        TNM classification of malignant tumors, fifth edition (1997). Union internationalecontre le cancer and the American Joint Committee on Cancer.
        Cancer. 1997; 80: 1803-1804
        • Fuhrman SA
        • Lasky LC
        • Limas C
        Prognostic significance of morphologic parameters in renal cell carcinoma.
        Am J Surg Pathol. 1982; 6: 655-663
        • Tomita M
        • Ayabe T
        • Chosa E
        • Nakamura K
        Prognostic significance of pre- and postoperative glasgow prognostic score for patients with non-small cell lung cancer.
        Anticancer Res. 2014; 34: 3137-3140
        • McMillan DC
        The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer.
        Cancer Treat Rev. 2013; 39: 534-540
        • Otowa Y
        • Nakamura T
        • Takiguchi G
        • et al.
        Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer.
        Dis Esophagus. 2016; 29: 146-151
        • Forrest LM
        • McMillan DC
        • McArdle CS
        • Angerson WJ
        • Dunlop DJ
        Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer.
        Br J Cancer. 2004; 90: 1704-1706
        • Al-Shaiba R
        • McMillan DC
        • Angerson WJ
        • Leen E
        • McArdle CS
        • Horgan P
        The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases.
        British J Cancer. 2004; 91: 205-207
        • McMillan DC
        • Scott HR
        • Watson WS
        • Preston T
        • Milroy R
        • McArdle CS
        Longitudinal study of body cell mass depletion and the inflammatory response in cancer patients.
        Nutr Cancer. 1998; 31: 101-105
        • Vasdev N
        • Altal Y
        • Mafeld S
        • et al.
        Can the Leibovich score for clear cell renal cell carcinoma (ccRCC) be accurately reported by a general pathologist?.
        BJU Int. 2014; 113: 581-585
        • Awakura Y
        • Nakamura E
        • Ito N
        • et al.
        Influence of body mass index on prognosis of Japanese patients with renal cell carcinoma.
        Urology. 2007; 70: 50-54
        • Jeon HG
        • Jeong IG
        • Lee JH
        • et al.
        Prognostic value of body mass index in Korean patients with renal cell carcinoma.
        J Urol. 2010; 183: 448-454
        • Kamat AM
        • Shock RP
        • Naya Y
        • Rosser CJ
        • Slaton JW
        • Pisters LL
        Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors.
        Urology. 2004; 63: 46-50
        • Schrader AJ
        • Rustemeier J
        • Rustemeier JC
        • et al.
        Overweight is associated with improved cancer-specific survival in patients with organ-confined renal cell carcinoma.
        J Cancer Res Clin Oncol. 2009; 135: 1693-1699
        • Waalkes S
        • Merseburger AS
        • Kramer MW
        • et al.
        Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer.
        Cancer Causes Control. 2010; 21: 1905-1910
        • Rogde AJ
        • Gudbrandsdottir G
        • Hjelle KM
        • Sand KE
        • Bostad L
        • Beisland C
        Obesity is associated with an improved cancer-specific survival, but an increased rate of postoperative complications after surgery for renal cell carcinoma.
        Scand J Urol Nephrol. 2012; 46: 348-357
        • Vigushin DM
        • Pepys MB
        • Hawkins PN
        Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease.
        J Clin Invest. 1993; 91: 1351-1357
        • Heikkila K
        • Ebrahim S
        • Lawlor DA
        A systematic review of the association between circulating concentrations of C reactive protein and cancer.
        J Epidemiol Comm Health. 2007; 61: 824-833